These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3108042)

  • 1. Significant increase of urinary low-sulfated heparan-sulfate-related protein in patients with severe systemic scleroderma.
    Kitabatake M; Ishikawa H; Uchiyama Y
    Dermatologica; 1987; 174(4):166-72. PubMed ID: 3108042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scleroderma-inducing glycosaminoglycan in the urine of patients with systemic scleroderma.
    Ishikawa H; Saito Y; Yamakage A; Kitabatake M
    Dermatologica; 1978; 156(4):193-204. PubMed ID: 564296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An approach to experimental scleroderma, using urinary glycosaminoglycans from patients with systemic scleroderma.
    Ishikawa H; Suzuki S; Horiuchi R; Sato H
    Acta Derm Venereol; 1975; 55(2):97-107. PubMed ID: 48324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte responsiveness to urinary glycosaminoglycan in systemic scleroderma.
    Ishikawa H; Hattori A
    Dermatologica; 1979; 158(5):328-33. PubMed ID: 312217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compositional changes of urinary acidic glycosaminoglycans in progressive systemic sclerosis.
    Murata K; Takeda M
    Clin Chim Acta; 1980 Nov; 108(1):49-59. PubMed ID: 6778637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glycosaminoglucuronates and their fractions in the urine of patients with scleroderma].
    Kowalczyk J; Oszewska Z
    Przegl Dermatol; 1978; 65(5):527-33. PubMed ID: 725096
    [No Abstract]   [Full Text] [Related]  

  • 7. [Urinary glycosaminoglycans in systemic scleroderma].
    Astakhova TA; Balabanova RM
    Ter Arkh; 1980; 52(12):100-5. PubMed ID: 7245055
    [No Abstract]   [Full Text] [Related]  

  • 8. Urinary glycosaminoglycan excretion in systemic sclerosis subsets compared with normal controls.
    Chuck AJ; Murphy J; Weiss JB; Jayson MI
    Br J Rheumatol; 1987 Aug; 26(4):259-61. PubMed ID: 3607377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical characterization of scleroderma-inducing glycosaminoglycan.
    Ishikawa H; Kitabatake M; Akiyama F
    Acta Derm Venereol; 1988; 68(5):378-84. PubMed ID: 2461019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scl-86, a marker antigen for diffuse scleroderma.
    van Venrooij WJ; Stapel SO; Houben H; Habets WJ; Kallenberg CG; Penner E; van de Putte LB
    J Clin Invest; 1985 Mar; 75(3):1053-60. PubMed ID: 3980727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Behavior of urinary acid mucopolysaccharides in dermatological collagen diseases].
    Rossi A
    G Ital Dermatol Minerva Dermatol; 1969 Dec; 44(12):641-5. PubMed ID: 4243640
    [No Abstract]   [Full Text] [Related]  

  • 12. A normal urinary excretion of acid mucopolysaccharides in generalized scleroderma.
    Ohlenschlaeger K; Friman C
    Scand J Clin Lab Invest; 1968; 21(4):364-8. PubMed ID: 4236504
    [No Abstract]   [Full Text] [Related]  

  • 13. Scleroderma and urinary excretion of acidic glycosaminoglycans.
    Hardy KH; Rosevear JW; Sams WM; Winkelmann RK
    Mayo Clin Proc; 1971 Feb; 46(2):119-27. PubMed ID: 4251060
    [No Abstract]   [Full Text] [Related]  

  • 14. Circadian rhythms and the urinary excretion of acid glycosaminoglycans in normal human adults.
    Newton DJ; Scott JE; Ahmad S
    Connect Tissue Res; 1979; 7(1):47-55. PubMed ID: 158486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urinary excretion of mucopolysaccharides in patients with collagen diseases (author's transl)].
    Kreysel HW; Köhler A
    Dermatologica; 1974; 148(1):19-27. PubMed ID: 4275497
    [No Abstract]   [Full Text] [Related]  

  • 16. Low urinary excretion of heparan sulfate in three patients with Lowe's syndrome.
    Yokoi T; Uozaki T; Kasei M; Sato T; Taniguchi N
    Clin Chim Acta; 1981 Oct; 116(2):153-60. PubMed ID: 6457705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-sulfated chondroitin sulfate in human blood and urine.
    Hata RI; Ohkawa SI; Nagai Y
    Biochim Biophys Acta; 1978 Oct; 543(2):156-66. PubMed ID: 728458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quantitative isolation of acid mucopolysaccharides from urine in progressive scleroderma (author's transl)].
    Kreysel HW; Kraus H; Stuhlsatz HW; Greiling E; Nissen HP; Kimmig J
    Arch Dermatol Res (1975); 1977 Jul; 259(1):11-9. PubMed ID: 143247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to demonstrate fibrotic changes in the skin of mice injected with glycosaminoglycan fractions from the urine of scleroderma patients.
    Fox PK; White DD; Cavanagh M; Davies MG; Wusterman F
    Dermatologica; 1982 Feb; 164(2):90-4. PubMed ID: 7075853
    [No Abstract]   [Full Text] [Related]  

  • 20. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.
    Chen Y; Leask A; Abraham DJ; Pala D; Shiwen X; Khan K; Liu S; Carter DE; Wilcox-Adelman S; Goetinck P; Denton CP; Black CM; Pitsillides AA; Sarraf CE; Eastwood M
    Arthritis Rheum; 2008 Feb; 58(2):577-85. PubMed ID: 18240216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.